Denmark's Curasight reports bigger Q4 loss

Curasight A/S

26/02/2026 07:14

Overview

Denmark radiopharmaceutical firm's Q4 2025 EPS improved yr/yr despite increased losses

Company dosed first patient in Phase 1 uTREAT trial for glioblastoma

Company strengthened balance sheet with DKK 63.4 mln cash and DKK 40 mln debt facilities

Outlook

Curasight expects top-line data from uTREAT® Phase 1 trial in 2026

Company anticipates top-line data from uTRACE® Phase 2 prostate cancer trial in 2026

Curasight focuses on disciplined execution and delivery of key clinical milestones in 2026

Result Drivers

uTREAT ADVANCEMENT - Co dosed first patient in Phase 1 uTREAT trial for glioblastoma, advancing clinical development

uTRACE PROGRESS - uTRACE continued to progress in Phase 2 prostate cancer trial, with top-line data expected in 2026

FINANCIAL POSITION - Co strengthened balance sheet with DKK 63.4 mln cash and DKK 40 mln debt facilities

Company press release: ID:nWkr2bKthK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-DKK 0.32
Q4 Net Income
-DKK 15.31 mln
Q4 Operating Income
-DKK 16.20 mln
Q4 Pretax Profit
-DKK 16.69 mln


Analyst Coverage

Wall Street's median 12-month price target for Curasight A/S is DKK8.00, about 51.4% below its February 25 closing price of DKK16.45

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)